Prolonging the Half-Life of Histone Deacetylase Inhibitor Belinostat via 50 nm Scale Liposomal Subcutaneous Delivery System for Peripheral T-Cell Lymphoma

Prolonging the Half-Life of Histone Deacetylase Inhibitor Belinostat via 50 nm Scale Liposomal Subcutaneous Delivery System for Peripheral T-Cell Lymphoma

Lymph node metastasis is an aggressive condition characterized by poor treatment outcomes and low overall survival. Belinostat is a novel histone deacetylase (HDAC) inhibitor approved by the Food and Drug Administration (FDA) for the treatment of relapsed peripheral T-cell lymphoma (PTCL). However,...

Full description

Bibliographic Details
Main Authors: Meng-Hsuan Cheng, Jun-Yi Weng, Chih-Hung Chuang, Wei-Ting Liao, Yu-Fong Lai, Jia-Yu Liu, Yi-Ping Fang
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Cancers
Subjects:
belinostat
peripheral T-cell lymphoma
liposome
drug delivery system
Online Access:https://www.mdpi.com/2072-6694/12/9/2558

Similar Items

Similar Items